endogenous retrovirus group K13 member 1Genealiases: []
Q-omics provides the consensus-scored ERVK13-1 profile across patient tissues and cancer cell-line models. ERVK13-1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, ERVK13-1 is differentially expressed in 6, with the highest sampling consensus in THCA. Additionally, ERVK13-1 RNA expression shows 20,771 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and THCA as cancer lineages where ERVK13-1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ERVK13-1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ERVK13-1 survival associations across molecular data types. ERVK13-1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ERVK13-1 RNA expression–survival associations across cancer types. High ERVK13-1 expression shows unfavorable associations in UVM, KIRC and LGG, but favorable associations in UCS, BLCA and READ. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for ERVK13-1 RNA expression.
This table summarizes ERVK13-1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for ERVK13-1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ERVK13-1 shows lower tumor expression in THCA, LUSC and UCEC and higher tumor expression in LIHC, CHOL and PRAD. The THCA box plot shows higher ERVK13-1 RNA expression in normal versus tumor tissue (log2 FC = −0.691, t-test p < 0.001).
This table shows molecular features associated with ERVK13-1 in patient tissues and cancer cell lines. In patient samples, ERVK13-1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ERVK13-1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD.
